Navigating Pituitary Tumors: Insights from an Italian Neurosurgical Survey
"Discover the latest trends in pituitary surgery across Italy, focusing on diagnosis, treatment approaches, and the vital role of multidisciplinary teams."
Pituitary tumors, typically benign, present unique diagnostic and management challenges. These tumors necessitate a deep understanding of anatomy, physiology, and pathology to ensure favorable outcomes. Optimal care hinges on tailored diagnostic tests and treatment guidelines.
Recognizing this imperative, a multicenter study was conducted across Italian neurosurgical centers. This initiative aimed to capture a real-world snapshot of current pituitary surgery practices from a neurosurgical perspective, ultimately seeking to enhance patient care and outcomes.
The study leveraged the collaborative framework of SINch (Società Italiana di Neurochirurgia) to survey 41 public institutions, exploring their activities and approaches in pituitary surgery. The goal was to identify best practices and areas for improvement within the Italian healthcare system.
Prevalence and Clinical Reach
Pituitary tumors account for approximately 17% of all primary brain tumors and affect 4.2 per 100,000 individuals per year. Most are histologically benign pituitary adenomas, which may remain undetected when they are small and nonfunctional. A 2022 international survey collected data from 254 departments in 34 countries; in 108 centers, or 42.5%, surgeons performed 100 adenoma surgeries annually.
Italian Pituitary Surgery: Key Findings & Trends
The survey engaged 37 of the 41 identified centers. Data analysis revealed that in 2016, a total of 1,479 neurosurgical procedures were performed for pituitary-related conditions. A significant majority of these interventions employed a transsphenoidal approach, with 1,320 cases utilizing this method (1,204 endoscopic, 53 microscopic, 53 endoscope-assisted microscopic), contrasting with 159 transcranial procedures.
- Transsphenoidal Approach Dominance: The preference for the transsphenoidal approach, especially the endoscopic technique, confirms its central role in pituitary surgery.
- Multidisciplinary Collaboration: The regular convening of multidisciplinary tumor boards in most centers underscores the value of collaborative expertise in diagnosis and treatment planning.
- Research Integration: The presence of research laboratories in several centers highlights a commitment to advancing knowledge and improving outcomes in pituitary care.
Evolving Surgical Evidence
An Italian study of first- and second-day postoperative growth hormone assessments reported that its findings require confirmation in larger cohorts and other neurosurgical centers. The international pituitary adenoma surgery survey found that 141 centers, or 56.8%, used an endoscopic approach in more than 90% of surgeries. A separate review describes hypothalamic-pituitary metastases as rare, representing 0.4% of intracranial metastatic tumors and 1.8% of surgically managed pituitary lesions.
The Giant-Tumor Dilemma
The optimal surgical treatment for giant pituitary neuroendocrine tumors remains debated, prompting an EANS Skull Base consensus effort. Clinically nonfunctioning giant pituitary adenomas are reported as more frequent than functioning tumors, exceeding 70% in the cited analysis and literature review. These tumors are generally discovered after pituitary hormone deficiency or mass effect on surrounding structures, underscoring the difficulty of treating advanced disease.
Risk and Surgical Strategy
A case report describes delayed, massive subarachnoid and intraventricular hemorrhage after transsphenoidal surgery for a suprasellar pituitary adenoma. In a separate cohort of 102 pituitary adenoma patients who underwent MR angiography or 3D-CT angiography, seven patients, or 6.9%, had intracranial aneurysms. Together, these reports highlight both a rare postoperative hemorrhagic event and the relevance of vascular assessment in selected patients.
The Future of Pituitary Care
The Italian survey reinforces the importance of teamwork, surgical expertise, and technological advancements in pituitary surgery. As medical knowledge expands, exchanging ideas and knowledge remains critical to refine treatment strategies and ensure the best possible outcomes for patients. High-volume centers with multidisciplinary teams and residency programs are poised to lead the way in enhancing pituitary care.
The Role of Expert Review
Neurological surgery expert witnesses may provide testimony on neurosurgery, brain tumors, brain surgery, stroke, trauma, and related conditions. Pituitary tumor expert witnesses and consultants may form expert opinions, draft reports, provide deposition or trial testimony, or serve as consulting experts. These listings show that pituitary tumor care can require specialized expert interpretation in addition to clinical management.
Responsible Innovation
Recent advances in pituitary surgery are described as promising ways to enhance quality of care. The reviewed work emphasizes that clinicians must remain gatekeepers of technological translation by systematically assessing risks and benefits. It presents neuroendoscopic treatment alongside advances in pathogenesis research, technology, clinical outcomes, and future directions.
Anatomy and Rare Disease
Pituitary tumors with cavernous sinus invasion represent a neurosurgical challenge. Safe and effective surgery requires a detailed understanding of cavernous sinus anatomy from an endonasal perspective. Pituitary metastases are also rare, representing approximately 1% of all pituitary tumors, and are associated with poor prognosis and limited published data.
Rare Disease and Breakthrough Care
The University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center reported the first-world complete remission of a rare pituitary cancer using a novel immunotherapy regimen. Separately, pituitary metastases account for approximately 1% of all pituitary tumors and are typically associated with a poor cancer prognosis. The most common reported primary sources of these metastases are lung cancer, at 39.7%, and breast cancer, at 23.7%.